Molecular diversity of hydroxamic acids: part II. Potential therapeutic applications.
A hydroxamic acid moiety has been demonstrated as the key structural element in many highly potent and selective inhibitors against a variety of metalloprotease enzymes, such as MMPs, TACE, HDAC, PDF, etc. Over the last several years, there has been a rapid growth of literature and patent applications dealing with the development of the hydroxamic acid-based inhibitors. This review highlights the most recent examples to show their potential therapeutic applications.
Lou
Boliang
B
Advanced SynTech, 9800 Bluegrass Parkway, Louisville, KY 40299, USA. blou@pharmaron.com
Yang
Kexin
K
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D045726:Metalloproteases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008958:Models, Molecular; D009369:Neoplasms / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D045726:Metalloproteases